Does a broad pattern of neural-reactive antibodies indicate immune reactivity?

Broad neural-antibody reactivity can be a meaningful immune signal, but its clinical significance depends on antibody specificity, titre, assay validity, specimen source, and whether there is objective evidence of CNS disease. This distinction is particularly important in older adults, in whom nonspecific or serum-only reactivity should not be equated with autoimmune neurologic disease or amyloid pathology.

Immune and diagnostic interpretation

• Broad reactivity is biologically plausible as an immune phenomenon. Defects in central or peripheral B-cell tolerance, and germinal-center somatic hypermutation, can allow multiple self-reactive B-cell clones and neural-reactive antibodies to emerge.
• It does not establish autoimmune brain disease. Autoimmune encephalitis requires a compatible subacute neurologic/psychiatric syndrome, supportive MRI, EEG, or CSF evidence, and exclusion of alternative causes. A well-characterized neuronal antibody can support a specific diagnosis only in this clinical setting.
• Serum-only results are especially limited: in a 2024 cohort, 46/148 (31%) serum-only positives were associated with probable/definite autoimmune encephalitis or paraneoplastic neurologic syndrome, versus 29/32 (91%) CSF-only positives.
• Assay choice materially affects apparent prevalence: validated antigen-specific methods had mean healthy-control serum positivity of 0.23%, compared with 5.8% using nonstandard methods.

Amyloid causality and mechanisms

• A broad antibody pattern does not show that antibodies cause amyloid accumulation. Experimental effects are target-specific: anti-BACE1 antibodies increased amyloid-beta production and deposition in APP/PS1 mice, proposed to involve PPARγ/BACE1 signaling.
• Other defined antibodies may have opposite effects; anti-amyloid-beta antibodies enhanced microglial uptake and reduced deposits in experimental models. Human autoimmune-encephalitis studies are retrospective and lack serial amyloid-PET evidence needed for causal inference.

Bottom line

• Neural-reactive antibodies should be treated as a hypothesis-generating finding, not proof of autoimmune brain disease or amyloid causation. Clinically meaningful interpretation requires validated target-specific testing, quantitative titres, paired serum/CSF assessment when appropriate, and correlation with symptoms and objective CNS findings.